3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, generic avapro 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM.

mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. generic avapro may also delay progression of diabetic nephropathy and is also indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). generic avapro is jointly marketed generic avapro sanofi-aventis and Bristol-Myers Squibb under the trade names to irbesartan preparations, including CoAprovel, generic avapro Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker generic avapro Clarke generic avapro Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; generic avapro Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist.

is indicated for the treatment of hypertension. Irbesartan was developed generic avapro Sanofi Research (now part of sanofi-aventis). It of.